Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The role of pentamidine for pneumocystis jirovecii prophylaxis in allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis

Muhammad Kashif Amin, Nabeeha Noor, Muhammad Talha Maqsood et al. Nov 03, 2025 pp. 7797-7797 10.1182/blood-2025-7797

Abstract Background: Pneumocystis jirovecii pneumonia (PJP) is a life-threatening opportunistic infection in allogeneic hematopoietic cell t...

Fecal microbiota transplantation ameliorates refractory chronic graft-versus-host disease through short-chain fatty acids-treg axis in allogeneic hematopoietic cell transplant recipients

Fen Huang, Qifa Liu Nov 03, 2025 pp. 7780-7780 10.1182/blood-2025-7780

Abstract Disruption of the intestinal microbiota plays a crucial role on the initial and development of graft-versus-host disease (GVHD). Fe...

Metabolomics profiling and machine learning prediction of efficacy and prolonged cytopenia in patients with large B-cell lymphoma undergoing CAR-T therapy

Hesong Zou, Chen Jia, Wei Liu et al. Nov 03, 2025 pp. 1938-1938 10.1182/blood-2025-1938

Abstract NTRODUCTION Achieving complete response (CR) within 3 months after CAR-T therapy is a key early indicator for predicting the long-t...

Efficacy, quality of life, and safety of non-clotting factor prophylaxis in Hemophilia A and b: A meta-analysis across inhibitor status

Abdul basit Khan, Rehan Ishaque, Sibgha Fawad Memon et al. Nov 03, 2025 pp. 6628-6628 10.1182/blood-2025-6628

Abstract Introduction: Hemophilia A and B are among the most common inherited bleeding disorders in humans with lifelong risk of spontaneous...

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Erika Morsia, Dorela Lame, Michelangelo Pianelli et al. Nov 03, 2025 pp. 7350-7350 10.1182/blood-2025-7350

Abstract Introduction Ruxolitinib has improved outcomes in both primary and secondary myelofibrosis (MF), though resistance or intolerance o...

Systematic review on the diagnostic evaluation of pediatric evans syndrome

Megan Askew, Ashley Geerlinks, Neeti Luke et al. Nov 03, 2025 pp. 6172-6172 10.1182/blood-2025-6172

Abstract Background: Evans syndrome (ES) is a complex disorder of multi-lineage autoimmune cytopenias and is often a chr...

Patient reported outcome design, conduct and reporting in australasian leukaemia & lymphoma group (ALLG) cooperative group trials

Arina Martynchyk, Jodie Palmer, Martina Chiarezza et al. Nov 03, 2025 pp. 4631-4631 10.1182/blood-2025-4631

Abstract Introduction: Patient reported outcomes (PROs) are recognised as critical components of clinical trials (CT) in...

The efficacy and safety of pirtobrutinib in patients with CLL/SLL: A phase 2 dose optimization trial in progress

Alexey Danilov, Alvaro Alencar, Jackson Gao et al. Nov 03, 2025 pp. 5690-5690 10.1182/blood-2025-5690

Abstract Introduction: The treatment landscape for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has...

Adverse events in Relapsed/Refractory multiple myeloma (RRMM) patients receiving bi-specific T-cell antibodies (BsAbs): A systematic review and meta-analysis of real-world evidence

Dongyu Zhang, Guoqiang Zhang, Julia Bui et al. Nov 03, 2025 pp. 7526-7526 10.1182/blood-2025-7526

Abstract Introduction: Bi-specific T-cell antibodies (BsAbs)—a type of immunotherapy used to treat relapsed/refractory multiple myeloma (RRM...

Safety and efficacy analysis of IV iron formulations in children: Results from a large pediatric cohort

Reeja Raj, Samanta Catueno, Kaleigh Riggs-Harpur et al. Nov 03, 2025 pp. 2906-2906 10.1182/blood-2025-2906

Abstract Introduction Iron deficiency (ID) is common in children, mostly due to dietary insufficiency or heavy menstrual...

Increased incidence of secondary malignancies after autologous stem cell transplantation in follicular lymphoma patients: Long-term results of the FIL-FLAZ12 Phase III randomized trial

Rita Tavarozzi, Andrea Evangelista, Manuela Zanni et al. Nov 03, 2025 pp. 5364-5364 10.1182/blood-2025-5364

Abstract Introduction Registry data, including European Society for Blood and Marrow Transplantation (EBMT) data (Petten...

Phase II study of reparixin in patients with myelofibrosis. myeloproliferative neoplasms research consortium (MPN-RC) 120 trial

Marina Kremyanskaya, Aaron Gerds, Rupali Bhave et al. Nov 03, 2025 pp. 3829-3829 10.1182/blood-2025-3829

Abstract Background/rationale Primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia (Post-PV/ET MF) (collectively...

Patient engagement and perceived impact of clinical trials in hematology

Elisabetta Abruzzese, Malgorzata Trawinska, Veronica Conti et al. Nov 03, 2025 pp. 8160-8160 10.1182/blood-2025-8160

Abstract Clinical trials are basic to therapeutic innovation and a vital opportunity for patients to access cutting-edge therapies. But how...

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Mikael Roussel, Juliette Ferrant, Ilenia Camille Manbangui et al. Nov 03, 2025 pp. 5332-5332 10.1182/blood-2025-5332

Abstract Introduction: CAR T-cells have significantly improved the prognosis of patients with relapsed or refractory (R/R) large B-cell lymp...

Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma

Thorstein Boxaspen, Hannah Cuthbertson Husbyn, Kim Anh Giang et al. Nov 03, 2025 pp. 2354-2354 10.1182/blood-2025-2354

Abstract T cell-based therapies have transformed the treatment landscape for multiple myeloma (MM). However, most patients receiving autolog...

In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20.

Yongke Zhang, yongkun yang, Jianwei Liu et al. Nov 03, 2025 pp. 2323-2323 10.1182/blood-2025-2323

Abstract Autologous chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies and multiple m...

Incidence and risk factors of hemophagocytic lymphohistiocytosis after bispecific antibody therapy in hematologic malignancies: Insights from a global real-world cohort

Kausik Maiti MD, Maria Ahmad, Nancy Lunney Nov 03, 2025 pp. 4763-4763 10.1182/blood-2025-4763

Abstract Background: Hemophagocytic lymphohistiocytosis (HLH) is a rare but life-threatening hyperinflammatory syndrome. It is increasingly...

Interferon therapy achieves potent reduction in JAK2 allele burden in patients with myeloproliferative neoplasms: A real-world analysis

Rachel Lazris, Laneisha Maldonado Jaime, Nikolaos Papadantonakis et al. Nov 03, 2025 pp. 7344-7344 10.1182/blood-2025-7344

Abstract Introduction: Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by aberrant JAK-STAT s...

Integrative proteomics and machine learning identify subtype- and symptom-associated signatures in systemic mastocytosis

Wei Xiao, Annie Hoai Nguyen, Ivo Veletic et al. Nov 03, 2025 pp. 3758-3758 10.1182/blood-2025-3758

Abstract Introduction: Systemic mastocytosis (SM) is a rare clonal disorder marked by the pathological accumulation of mast cells, key effect...

Evaluation of clinical significance of circulating growth differentiation factor-15 levels in patients with gaucher disease

Veroniki Komninaka, Aimilia Mantzou, Nikolaos Tsagarakis et al. Nov 03, 2025 pp. 4755-4755 10.1182/blood-2025-4755

Abstract Background: Gaucher disease (GD) is a rare autosomal recessive genetic disorder resulting from mutations in the GBA1 gene located o...

9-year-old female presenting with l lower leg pain diagnosed with erdheim-chester disease (ECD)

Jessica Zon, Jason White, Nataly Apollonsky et al. Nov 03, 2025 pp. 7334-7334 10.1182/blood-2025-7334

Abstract Background: Erdheim-Chester disease (ECD) is a non-Langerhans histiocytic disorder that commonly includes osteosclerotic lesions of...

Role of therapeutic anticoagulation in kidney transplant recipients with thrombophilia: A systematic review

Zain Al-Momani, Vasu Bansal, Harshit Khosla et al. Nov 03, 2025 pp. 4914-4914 10.1182/blood-2025-4914

Abstract Background: Renal allograft thrombosis, though commonly attributed to surgical or anatomical causes, is increasingly linked to inhe...

Influence of HIV status, age and ethnicity on survival in patients with burkitt lymphoma (BL) and diffuse large B cell lymphoma (DLBCL): A real-world nationwide database study

Himil Mahadevia, Tarunjot Sethi, An-Lin Cheng et al. Nov 03, 2025 pp. 2726-2726 10.1182/blood-2025-2726

Abstract Introduction: BL and DLBCL are the two most common lymphomas associated with HIV infection. Notably, clinical trials often exclude...

Feasibility of wearable technology for remote monitoring in high-risk adults with sickle cell disease: Baseline data from the SCD-carre trial

Charles Jonassaint, Alicia Colvin, Colleen Ballantyne et al. Nov 03, 2025 pp. 2600-2600 10.1182/blood-2025-2600

Abstract Background: Adults with sickle cell disease (SCD) experience reduced physical capacity due to anemia and cardiopulmonary complicati...

Temporal trends in aplastic anemia mortality across u.S. regions (1999–2020)

Preny Karamian, Ubaid Ahmed, Aqsa Hafeez et al. Nov 03, 2025 pp. 6725-6725 10.1182/blood-2025-6725

Abstract Introduction: Aplastic anaemia is a life-threatening, rare disease with high rate mortality. Even though the pathophysiology of the...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page